Sagimet Biosciences (SGMT) Accumulated Expenses (2022 - 2026)
Sagimet Biosciences (SGMT) posted quarterly Accumulated Expenses of $579000.0 for Q1 2026, up 36.88% year-over-year from $423000.0 in Q1 2025, and down 84.41% quarter-over-quarter from $3.7 million in Q4 2025.
Sagimet Biosciences (SGMT) Accumulated Expenses (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Accumulated Expenses history runs 5 years deep, the most recent figure standing at $579000.0 for Q1 2026.
- In Q1 2026, Accumulated Expenses rose 36.88% year-over-year to $579000.0; the TTM figure through Mar 2026 stood at $579000.0 (up 36.88% YoY), while the FY2025 annual figure was $3.7 million, up 25.86% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $579000.0, down from $3.7 million in the prior quarter.
- The five-year high for Accumulated Expenses was $5.4 million in Q4 2023, with the low at $423000.0 in Q1 2025.
- The 5-year median for Accumulated Expenses is $3.2 million (2023), against an average of $2.8 million.
- Peak annual rise in Accumulated Expenses reached 381.21% in 2025, while the deepest fall reached 89.3% in 2025.
- Sagimet Biosciences' Accumulated Expenses stood at $4.0 million in 2022, then soared by 34.37% to $5.4 million in 2023, then plunged by 45.38% to $3.0 million in 2024, then gained by 25.86% to $3.7 million in 2025, then plunged by 84.41% to $579000.0 in 2026.
- Business Quant data shows SGMT's Accumulated Expenses at $579000.0 in Q1 2026, $3.7 million in Q4 2025, and $4.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.20 Mn |
| Mar 31, 2026 | 579,000.00 |
| Dec 31, 2025 | 3.71 Mn |
| Sep 30, 2025 | 4.79 Mn |
| Jun 30, 2025 | 865,000.00 |
| Mar 31, 2025 | 423,000.00 |
| Dec 31, 2024 | 2.95 Mn |
| Sep 30, 2024 | 995,000.00 |
| Jun 30, 2024 | 3.58 Mn |
| Mar 31, 2024 | 3.95 Mn |
| Dec 31, 2023 | 5.40 Mn |
| Sep 30, 2023 | 3.24 Mn |
| Jun 30, 2023 | 2.42 Mn |
| Dec 31, 2022 | 4.02 Mn |